Developmental Dysplasia of the Hip
Conditions
Interventions
One-stage replacement group:Bilateral total hip arthroplasty was performed under a single anesthesia
Two-stage replacement group:A unilateral total hip arthroplasty was performed under anesthesia once, and a total hip arthroplasty on the other side was carried out again after some time
Sponsors
Chinese PLA general hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. The subjects were patients with bilateral DDH. 2. Age: 18 to 85 years old. 3. According to the judgment of the clinical researchers, the subjects can understand this clinical study and cooperate to complete the research process. 4. Before the start of the study, the subjects were willing and able to sign the informed consent form approved by the Institutional Review Board (IRB), Ethics Committee (EC), or Ethics Review Board (ERB). 5. The subjects are capable of expressing, reading and understanding the questions in the subject subjective questionnaire stipulated in the research protocol, and can provide feedback information in appropriate language.
Exclusion criteria
Exclusion criteria: 1. Patients with high expectations of pain relief, gait recovery, and limb length. 2. Patients who are physically and mentally unhealthy and unable to cooperate with the trial cannot provide written consent to voluntarily participate in the clinical study. 3. Subjects are pregnant or lactating women. 4. The affected hip joint has undergone Girdlestone or surgical fusion. 5. Amputation above the knee joint of the contralateral or ipsilateral lower limb. 6. Subject has an active infection. 7. Subjects have diseases or adverse health conditions that the investigator believes may affect their participation in this study, such as malignant diseases, serious illnesses, alcohol or drug addiction, and/or mental disorders. 8. Subjects suffer from severe osteoporosis, metabolic bone disease, radiation bone disease, or perihip tumors that the investigator believes have a negative impact on internal plant fixation or research results. 9. Subject has a severe neurological or musculoskeletal disease that may affect gait or weight bearing, (e.g.: muscular dystrophy, multiple sclerosis, cerebral infarction, hemiplegia, Charcot's disease). 10. Subjects cannot express, read, and understand the questions in the subjective questionnaire specified in the study protocol, and cannot provide feedback in appropriate language. 11. Subjects suffer from other diseases and have a life expectancy of less than 2 years. 12. Other diseases combined with the subject restrict their participation in the study, unable to comply with follow-up or affect the scientific integrity of the study. 13. Subject is currently participating in another drug or device clinical study. 14. Subject is serving a sentence. 15. Subject is known to be allergic to any component of the endoplant (e.g., metal).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Harris score; | — |
Secondary
| Measure | Time frame |
|---|---|
| SF-12 score;VAS score;BPFS score;ASA score;Time of operation;Peroperative bleeding;All-in cost; | — |
Countries
China
Contacts
Public ContactChai Wei
Chinese PLA general hospital
Outcome results
None listed